Inr is 2,9 and patient having b/l upper limb thrombosis with ischaemia
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
bilateral upper limb arterial thrombosis ischemia management
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Now I have excellent source material. Let me compile the comprehensive response.
Clinical Analysis: INR 2.9 + Bilateral Upper Limb Thrombosis with Ischaemia
This is a critical clinical paradox - thrombosis occurring despite apparent anticoagulation (INR 2.9). This demands urgent systematic evaluation.
Step 1: Identify the Underlying Diagnosis
The combination of thrombosis + apparent anticoagulation should immediately trigger the following differential:
1. Heparin-Induced Thrombocytopenia (HIT) - TOP PRIORITY
If this patient is on or has recently received heparin (including flushes, LMWH, heparin-coated catheters):
| Feature | HIT Details |
|---|---|
| Mechanism | IgG antibodies against heparin-PF4 complex → platelet activation → massive thrombin generation |
| Timing | Platelet fall 5-14 days after heparin start; can be acute (<24h) if prior heparin exposure in last 3 months |
| Thrombosis pattern | Venous > arterial; arterial includes limb ischaemia, stroke, MI |
| Key paradox | Thrombosis despite anticoagulation, platelet count drops ≥50% from baseline |
The INR of 2.9 in this setting is dangerously misleading - if the patient was on warfarin AND developed HIT, the supratherapeutic INR reflects protein C depletion and does NOT protect against thrombosis. Warfarin in acute HIT can cause venous limb gangrene by further depleting protein C.
- Goldman-Cecil Medicine, HEPARIN-INDUCED THROMBOCYTOPENIA section
2. Antiphospholipid Syndrome (APS)
- Recurrent arterial and/or venous thrombosis despite anticoagulation
- Lupus anticoagulant can falsely elevate INR (prolonged aPTT), giving a misleading picture of "adequate" anticoagulation
- Catastrophic APS: multisystem thrombosis, fatal in up to 30% - must be excluded
3. Catastrophic APS
- Simultaneous multi-organ/limb thrombosis
- May present with bilateral limb involvement
4. Warfarin Resistance / Paradoxical Thrombosis
- Supratherapeutic INR does NOT rule out hypercoagulable states
- Early warfarin causes transient protein C/S depletion that can paradoxically worsen thrombosis
Step 2: Immediate Management
A. STOP all heparin immediately (if HIT suspected)
This includes:
- Subcutaneous LMWH/UFH
- Heparin flushes
- Heparin-coated catheters (remove)
- Do NOT restart even if "needed"
B. Do NOT give platelet transfusions
- In HIT, platelets fuel thrombus formation - transfusions can worsen thrombosis
C. Switch to Alternative Anticoagulation (non-heparin)
| Agent | Notes |
|---|---|
| Argatroban (IV direct thrombin inhibitor) | FDA-approved for HIT; preferred if renal impairment present (hepatic clearance) |
| Bivalirudin (IV direct thrombin inhibitor) | Alternative; approved for HIT in PCI setting; renally cleared - caution in renal failure |
| Fondaparinux (SC factor Xa inhibitor) | Effective, not FDA-approved for HIT, renally cleared |
| Rivaroxaban | Emerging use; 15 mg BD x 21 days then 20 mg OD (similar to acute VTE dosing) |
| Apixaban | Also used; doses as per acute VTE protocol |
Do NOT use warfarin in acute HIT - it risks venous limb gangrene. Only transition to warfarin once platelets return to baseline (typically >150,000/μL) and overlap with parenteral anticoagulant for ≥5 days.
- Goldman-Cecil Medicine, TREATMENT AND PREVENTION section
- Braunwald's Heart Disease, HIT management section
D. Manage limb ischaemia
- Urgent vascular surgery/interventional radiology consult for bilateral upper limb ischaemia
- Options include:
- Catheter-directed thrombolysis (if no contraindications to lysis)
- Surgical embolectomy/thrombectomy - Fogarty catheter technique
- Angiography to delineate extent
- Ensure adequate non-heparin anticoagulation during any procedure
Step 3: Urgent Investigations
| Investigation | Reason |
|---|---|
| Platelet count + trend | Drop ≥50% from baseline = HIT until proven otherwise |
| Anti-PF4/heparin ELISA | Sensitive (99%) for HIT antibodies; negative essentially rules out HIT |
| Serotonin Release Assay | Gold standard for HIT (specificity >95%), but takes days |
| 4T Score | Pre-test probability scoring for HIT (Thrombocytopenia, Timing, Thrombosis type, other cause for Thrombocytopenia) |
| Antiphospholipid antibodies | Anticardiolipin IgG/IgM, anti-β2-glycoprotein I, lupus anticoagulant |
| Coagulation screen | PT/INR, aPTT, fibrinogen, D-dimer (rule out DIC) |
| Peripheral blood film | Microangiopathy, schistocytes (TTP/HUS) |
| ANA, complement | Rule out SLE/catastrophic APS |
| CT angiography of upper limbs | Extent of thrombosis, arterial vs. venous, planning intervention |
| Echocardiogram | Cardiac source of embolism; intracardiac thrombus |
Step 4: The INR 2.9 - What Does It Mean Here?
The supratherapeutic INR (target usually 2.0-3.0 for standard indications) does NOT indicate effective protection against thrombosis in:
- HIT (pro-thrombotic mechanism overwhelms INR)
- APS with lupus anticoagulant (lupus anticoagulant falsely prolongs PT in vitro - INR may not reflect actual anticoagulation)
- Active thrombotic states consuming clotting factors (consumption coagulopathy)
An INR of 2.9 in the presence of thrombosis is a red flag for one of these conditions, not reassurance.
Step 5: 4T Score for HIT
| Parameter | Score 2 | Score 1 | Score 0 |
|---|---|---|---|
| Thrombocytopenia | >50% fall, nadir ≥20K | 30-50% fall, nadir 10-19K | <30% fall, nadir <10K |
| Timing | Day 5-10, or ≤1 day if prior heparin | >10 days, or timing unclear | <4 days (no prior heparin) |
| Thrombosis | New thrombosis, skin necrosis | Progressive/recurrent thrombosis | None |
| oTher cause for thrombocytopenia | None identified | Possible | Definite other cause |
- Score 6-8: High probability (>80% likelihood of HIT) - treat as HIT immediately
- Score 4-5: Intermediate
- Score 0-3: Low probability
Key Takeaway
Bilateral upper limb thrombosis + ischaemia in an anticoagulated patient (INR 2.9) = HIT until proven otherwise. This is a vascular emergency requiring:
- Immediate heparin cessation
- Platelet count check + 4T score assessment
- Urgent anti-PF4 ELISA
- Switch to argatroban/bivalirudin/fondaparinux immediately (do not wait for results if clinical suspicion is high)
- Emergency vascular intervention for limb ischaemia
- Rule out APS/catastrophic APS in parallel
This clinical scenario carries high morbidity and mortality if not acted on within hours.
This is a shared conversation. Sign in to Orris to start your own chat.